NYSE: BAX

Baxter International (BAX) Stock Analysis & Forecast

Nov 13 close

$25.81+0.07 (+0.3%)

Gekko Brief

AI summaryNov 9 close

Baxter International shares have been volatile this week, swinging between gains and losses across choppy sessions, with the stock recently outperforming or underperforming the broader market on different days amid a generally negative tape for the S&P 500 and Dow. Barclays maintained its Underweight rating on the stock but raised its price target to $23 from $20, a move it frames against a closing price of $25.79. The company's Q3 2026 results, reported 29 October, showed global sales of approximately $3 billion, up 5% on both reported and organic bases, with adjusted EPS of $0.58 beating the $0.52 estimate, led by Advanced Surgery, Drug Compounding, and Infusion Systems.

BAX closed at $26.41, up 2.4%, sitting above both its 50-day ($24.51) and 200-day ($21.51) moving averages, with the shorter average above the longer one. The GekkoIndex reads 54, placing the stock in the Neutral zone, down from a five-day change of -9.5. The price sits 3.6% above Gekko Fair Value of $25.50.

The next earnings date is 11 February 2027, 88 days away, outside a typical 20-trading-day holding window. No insider, Congress, or unusual options activity appears in their respective windows. Seasonality over the next 20 trading days has averaged -1.2% across 5 years, with gains in 3 of them. Consensus among 7 analysts stands at 0 buy, 6 hold, 1 sell, with a consensus target of $27, implying 2.2% upside.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Baxter International price vs fair value

$25.81$25.62Nov ’25May ’26Nov ’26
Close $25.81200-day averageGekko Fair Value $25.62

Baxter International quick facts

Market cap
$13.35B
P/E ratio
—
Forward P/E
12.5
EPS, TTM
−$1.21
Revenue, TTM
$11.61B
Profit margin
-6.2%
Dividend yield
0.15%
Beta
0.67
Volume
4.49M avg 7.51M
1-year return
+38.0%
Typical daily move
±4.6%
Typical 20-day move
±6.6%
50-day average
$24.54
200-day average
$21.64
Next earnings
Feb 11 before open
Shares outstanding
517.3M
52-week range
$15.73$30.00

Baxter International swing-trade checklist

Baxter International scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $25.81 is above the 50-day ($24.54) and 200-day ($21.64) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    56.1, Neutral

    Reading 56.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.7% above

    Price is within 5% of Gekko Fair Value (0.7% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 88 days

    Next report Feb 11, 2027, 88 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +2.5% on average

    From this point in the calendar, the next 20 trading days averaged +2.5% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Baxter International stock chart and price history

Baxter International closed at $25.81 on Nov 13, 2026, +38.0% over the past year, inside a 52-week range of $15.73 to $30.00.

Close50-day average200-day averageVolume
Baxter International share price, past year, with 50-day and 200-day moving averages and volume$20DecJan 2026FebMarAprMayJunJulAugSepOctNov25.81

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+0.2%
3 months
−0.4%
6 months
+49.2%
1 year
+38.0%
The full BAX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BAX in Gekko

Follow Baxter International through every session

Put BAX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track BAX in GekkoFree for 7 days. No credit card required.

About Baxter International

Baxter International makes a broad range of healthcare products used in treating serious and chronic conditions. Its offerings span dialysis care for kidney patients, intravenous fluids and infusion equipment, drug compounding and pharmacy services, nutrition therapies given outside normal eating, and surgical products used to control bleeding, seal tissue and limit adhesions during operations. It is also recognized for connected care systems that combine monitoring devices, software and communication tools used across hospitals and clinics.

The company reaches patients through hospitals, dialysis centers, nursing and rehabilitation facilities, doctors' offices, and home care settings. It sells through a mix of its own sales staff, independent distributors, drug wholesalers and specialty pharmacies, and it works with roughly 100 countries worldwide. Baxter also performs contract work for other pharmaceutical and biopharmaceutical firms, and has a partnership with Celerity Pharmaceutical focused on generic injectable and oncolytic drug development.

Baxter International was founded in 1931 and is headquartered in Deerfield, Illinois. Its shares are listed on the NYSE under the ticker BAX.

Listed
NYSE
Sector
Health technology
Industry
Medical specialties
Website
baxter.com

Baxter International GekkoIndex: the smart money zone

Baxter International’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 56.1, in the Neutral zone, up 0.9 points over five sessions.

010056.1Neutral

Up 0.9 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying84+0.1%−0.5%+0.4%+4.1%
Accumulation238−0.4%−0.5%−1.4%−2.0%
Neutral (current zone)3530.0%−0.2%−0.5%−4.3%
Distribution26−1.3%−0.5%−1.9%−4.2%
Selling1Too few readings yet

Average BAX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the BAX price, zone by zone.Track BAX in Gekko

Is Baxter International stock overvalued? Gekko Fair Value

Baxter International trades 0.7% above Gekko Fair Value of $25.62, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Baxter International shares are worth, recalculated every trading day.

$25.62

Gekko Fair Value, Nov 13, 2026

0.7% above fair value · About fair value

At the end of Aug 2026 the price was 4.3% below the estimate.

Gekko Fair ValueShare price, month end
$26$26Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open BAX in Gekko

Baxter International insider and Congress trading

No open-market insider purchases were filed for Baxter International, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for BAX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every BAX insider filing, plotted on the chart in Gekko.Open BAX in Gekko

Congress trades last 90 days

No trades in BAX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for BAX, plotted on the chart in Gekko.Open BAX in Gekko

Buybacks

Baxter International has been buying back its own shares.

Bought back, quarter ended Sep 30, 2022
$32.00M
As a share of market cap
0.24%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

0of the funds Gekko tracks hold BAX.

0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko

Baxter International earnings: next date and track record

Baxter International reports on Feb 11, 2027, before the open (88 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±9.9%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

+9.7%Feb ’25−1.5%May ’25−21.7%Jul ’25−17.6%Oct ’25−11.2%Feb ’26+1.8%Apr ’26+5.6%Jul ’26−9.7%Oct ’26

Last earnings call, Oct 29, 2026 AI summary

What they said
Baxter International reported Q3 2026 global sales of approximately $3 billion, up 5% on both reported and organic basis with broad-based growth across all divisions. Adjusted EPS came in at $0.58 per diluted share, exceeding expectations but down year-over-year due to prior year discrete tax benefits. Advanced Surgery, Drug Compounding, and Infusion Systems were top contributors. The company is raising full-year organic sales growth guidance and EPS outlook, citing turnaround progress.
Guidance
Baxter raised full-year 2026 organic sales growth outlook to 3%-4% from prior 2%-3%. Adjusted EPS guidance raised to $2.05-$2.15, up from the low end of $1.95-$2.15 previously. Management expects stronger second-half performance consistent with their stated annual framework.
ReportedEPSSurpriseRevenueSurpriseMove
Oct 29, 2026$0.58
est $0.52
+12.0%$2.98B
est $2.91B
+2.3%−9.7%
Jul 30, 2026$0.56
est $0.36
+55.6%$2.96B
est $2.80B
+5.9%+5.6%
Apr 30, 2026$0.36
est $0.31
+16.1%$2.70B
est $2.62B
+3.3%+1.8%
Feb 12, 2026$0.44
est $0.55
−19.6%$2.97B
est $2.82B
+5.3%−11.2%
Oct 30, 2025$0.69
est $0.60
+15.0%$2.84B
est $2.82B
+0.4%−17.6%
Jul 31, 2025$0.59
est $0.61
−3.3%$2.81B
est $2.88B
−2.3%−21.7%
May 1, 2025$0.55
est $0.48
+14.6%$2.63B
est $2.59B
+1.4%−1.5%
Feb 20, 2025$0.58
est $0.52
+11.5%$2.75B
est $2.67B
+3.0%+9.7%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Baxter International stock forecast and analyst price targets

Analysts’ average 12-month price target for Baxter International is $27.25, +5.6% from the last close, from 6 firms rating the stock in the last 90 days.

$27.25consensus 12-month target, +5.6% from the last close
Low $23High $27
Buy0
Hold5
Sell1

Each firm’s latest rating in the last 90 days: 6 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9BarclaysSell, maintained$23−10.9%
Nov 6BarclaysSell, maintained$23−10.9%
Oct 30Stifel NicolausHold, maintained$25−3.1%
Oct 30Wells FargoHold, maintained$25−3.1%
Oct 30J.P. MorganHold, maintained$25−3.1%
−0.5%average 20-day move after past Neutral readings
+2.5%average move over the next 20 trading days in the last 5 years
±4.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Baxter International seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Baxter International averaged +2.5% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

+3.7%2021−1.0%2022+9.5%2023−4.4%2024+5.7%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days+1.3%2 of 5
Next 10 trading days+1.6%4 of 5
Next 15 trading days−0.6%2 of 5
Next 20 trading days+2.5%3 of 5
Next 30 trading days+2.1%3 of 5

For scale, BAX’s typical 20-trading-day move in either direction is about 6.6%.

Baxter International market cap and key statistics

Baxter International’s market cap is $13.35B and revenue of $11.61B over the last twelve months.

Valuation

Market cap
$13.35B
Forward P/E
12.5
EPS, TTM
−$1.21
Gekko Fair Value
$25.62

Trading

Volume
4.49M
Avg volume, 20 days
7.51M
52-week high
$30.00
52-week low
$15.73
Shares outstanding
517.3M

Financials

Revenue, TTM
$11.61B
Profit margin
-6.2%
Return on equity
-9%
Quarterly earnings growth, YoY
+36.8%

Risk and income

Beta
0.67
Typical daily move
±4.6%
Typical 20-day move
±6.6%
Dividend yield
0.15%

Baxter International peers

Baxter International’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
TMOThermo Fisher Scientific−0.2%Neutral15.0% above
ABTAbbott Laboratories+0.3%Neutral10.5% below
DHRDanaher0.0%Neutral4.7% above
ISRGIntuitive Surgical0.0%Neutral17.5% above
MDTMedtronic+0.7%Neutral14.2% below
SYKStryker−2.0%Neutral0.1% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Medical specialties

Baxter International stock FAQ

What is Baxter International’s market cap?

Baxter International’s market cap is $13.35B at the Nov 13, 2026 close of $25.81, with 517.3M shares outstanding.

What is the Baxter International stock forecast?

The consensus analyst 12-month price target for Baxter International is $27.25, +5.6% from the last close. Of the 6 firms that rated the stock in the last 90 days, 0 rate it a buy, 5 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Baxter International stock overvalued or undervalued?

On Gekko’s estimate Baxter International is about fair value: the Nov 13, 2026 close of $25.81 is 0.7% above Gekko Fair Value of $25.62. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Baxter International report earnings next?

Baxter International is expected to report on Feb 11, 2027, before the market opens (88 days away). Analysts expect earnings of $0.60 per share on revenue of $3.09B. Baxter International beat the earnings estimate in 6 of its last 8 reports, moving 9.9% on average across the report.

What is Baxter International’s 52-week high and low?

Baxter International’s 52-week high is $30.00 and its 52-week low is $15.73; it closed at $25.81 on Nov 13, 2026, +38.0% over the past year. Over the last five years the shares peaked at $89.70 on Feb 9, 2022.

Is Baxter International stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Baxter International the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.